Ascendis Pharma A (ASND) Current Deferred Revenue (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Current Deferred Revenue data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 401.69% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (up 401.69% YoY), and the FY2025 full-year result was $5.8 million, up 6.34% from the prior year.
• Current Deferred Revenue climbed to $6.3 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $13.3 million in Q3 2022 to a low of -$10.1 million in Q3 2023.
• A 5-year average of $4.0 million and a median of $5.4 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 3539.29% in 2022 and tumbled 351.48% in 2023, its largest moves.
• Tracing ASND's Current Deferred Revenue over 5 years: stood at $8.8 million in 2022, then decreased by 27.45% to $6.4 million in 2023, then declined by 16.53% to $5.3 million in 2024, then gained by 7.71% to $5.8 million in 2025, then gained by 9.12% to $6.3 million in 2026.
• Business Quant data shows ASND's Current Deferred Revenue at $6.3 million in Q1 2026, $5.8 million in Q4 2025, and $4.9 million in Q3 2025.